AGILENT TECHNOLOGIES, INC.
AAPI behind this page
A Q3 2025 request
Playground key active
/api/financials?ticker=A&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 1,738 | 1,578 | +10.1% |
Show Product Lines breakouts |
|||
| Instrumentation | 599 | 556 | +7.7% |
| Non-Instrumentation and Other | 1,139 | 1,022 | +11.4% |
| Product | 1,230 | 1,121 | +9.7% |
| Service Other | 508 | 457 | +11.2% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 744 | 691 | +7.7% |
| Agilent CrossLab · Americas | 274 | 267 | +2.6% |
| Agilent CrossLab · Asia Pacific | 258 | 240 | +7.5% |
| Agilent CrossLab · Europe | 212 | 184 | +15.2% |
| Applied Markets | 324 | 302 | +7.3% |
| Applied Markets · Americas | 93 | 91 | +2.2% |
| Applied Markets · Asia Pacific | 152 | 140 | +8.6% |
| Applied Markets · Europe | 79 | 71 | +11.3% |
| Life Sciences and Diagnostics Markets | 670 | 585 | +14.5% |
| Life Sciences and Diagnostics Markets · Americas | 316 | 268 | +17.9% |
| Life Sciences and Diagnostics Markets · Asia Pacific | 153 | 140 | +9.3% |
| Life Sciences and Diagnostics Markets · Europe | 201 | 177 | +13.6% |
Show Geography breakouts |
|||
| Americas | 683 | 626 | +9.1% |
| Asia Pacific | 563 | 520 | +8.3% |
| Europe | 492 | 432 | +13.9% |
Show End Markets [Axis] breakouts |
|||
| Academic and Government | 132 | 128 | +3.1% |
| Chemicals and Advanced Materials | 399 | 356 | +12.1% |
| Diagnostics and Clinical | 258 | 242 | +6.6% |
| Environmental and Forensics | 163 | 168 | -3.0% |
| Food | 157 | 144 | +9.0% |
| Pharmaceutical and Biopharmaceutical | 629 | 540 | +16.5% |
| Cost of Revenue | 850 | 723 | +17.6% |
Show Product Lines breakouts |
|||
| Product | 577 | 491 | +17.5% |
| Service Other | 273 | 232 | +17.7% |
| Total Costs & Expenses | 1,378 | 1,245 | +10.7% |
| Research & Development | 111 | 127 | -12.6% |
| Selling, General & Administrative | 417 | 395 | +5.6% |
| Operating Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 77 | 99 | -22.2% |
| Operating Income | 360 | 333 | +8.1% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 248 | 248 | 0.0% |
| Applied Markets · Operating Segments | 71 | 70 | +1.4% |
| Life Sciences and Diagnostics Markets · Operating Segments | 118 | 114 | +3.5% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 437 | 432 | +1.2% |
| Interest Income | 16 | 19 | -15.8% |
| Other Non-Operating Income (Expense) | 18 | 13 | +38.5% |
| Income Before Taxes | 366 | 343 | +6.7% |
| Income Tax Expense (Benefit) | 30 | 61 | -50.8% |
| Net Income | 336 | 282 | +19.1% |
Show Equity Components breakouts |
|||
| Parent | 336 | 282 | +19.1% |
| Retained Earnings | 336 | 282 | +19.1% |
| Comprehensive Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Parent | 333 | 288 | +15.6% |
| EPS (Basic) | 1.18 | 0.97 | +21.6% |
| EPS (Diluted) | 1.18 | 0.97 | +21.6% |
| Wtd Avg Shares (Basic) | 284 | 290 | -2.1% |
| Wtd Avg Shares (Diluted) | 285 | 291 | -2.1% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | 2 | -3 | +166.7% |
| Interest Expense | -28 | -22 | -27.3% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,535 | 1,779 | -13.7% |
| Accounts Receivable | 1,382 | 1,227 | +12.6% |
| Inventory | 1,014 | 978 | +3.7% |
| Total Current Assets | 4,253 | 4,256 | -0.1% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 1,966 | 1,446 | +36.0% |
| Operating Lease Right-of-Use Assets | 179 | 178 | +0.6% |
| Goodwill | 4,475 | 3,965 | +12.9% |
Show Business Segments breakouts |
|||
| Agilent CrossLab | 1,168 | 259 | +351.0% |
| Applied Markets | 309 | — | — |
| Life Sciences and Diagnostics Markets | 2,998 | — | — |
| Other Non-Current Assets | 930 | 751 | +23.8% |
| Total Assets | 12,226 | 10,996 | +11.2% |
Show Business Segments breakouts |
|||
| Agilent CrossLab · Operating Segments | 2,427 | 916 | +165.0% |
| Applied Markets · Operating Segments | 882 | — | — |
| Life Sciences and Diagnostics Markets · Operating Segments | 5,997 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 2,920 | 2,988 | -2.3% |
| Long Term Investments | 133 | 186 | -28.5% |
| Current Liabilities | |||
| Accounts Payable | 530 | 497 | +6.6% |
| Deferred Revenue | 620 | 524 | +18.3% |
| Total Current Liabilities | 1,892 | 2,389 | -20.8% |
| Non-Current Liabilities | |||
| Long-Term Debt | 3,350 | — | — |
Show Debt Instrument breakouts |
|||
| Other Loans | 21 | — | — |
| Senior Notes | 3,329 | — | — |
| Senior Notes 2026 | 300 | — | — |
| Senior Notes 2027 | 597 | — | — |
| Senior Notes 2029 | 497 | — | — |
| Senior Notes 2030 | 497 | — | — |
| Senior Notes 2031 | 845 | — | — |
| Senior Notes 2034 | 593 | — | — |
| Other Non-Current Liabilities | 495 | 471 | +5.1% |
| Total Liabilities | 5,856 | 5,093 | +15.0% |
| Stockholders' Equity | |||
| Common Stock | 3 | 3 | 0.0% |
| Additional Paid-In Capital | 5,548 | 5,458 | +1.6% |
| Retained Earnings | 1,102 | 773 | +42.6% |
| Accumulated Other Comprehensive Income | -283 | — | — |
| Total Stockholders' Equity | 6,370 | 5,903 | +7.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -283 | -331 | +14.5% |
| Additional Paid In Capital | 5,548 | 5,458 | +1.6% |
| Common Stock | 3 | 3 | 0.0% |
| Parent | 6,370 | 5,903 | +7.9% |
| Retained Earnings | 1,102 | 773 | +42.6% |
| Total Liabilities & Equity | 12,226 | 10,996 | +11.2% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 217 | 188 | +15.4% |
| Stock-Based Compensation | 102 | 103 | -1.0% |
| Deferred Income Taxes | -35 | -8 | -337.5% |
| Other Non-Cash Items | -4 | -2 | -100.0% |
| Change in Accounts Receivable | -44 | 67 | -165.7% |
| Change in Inventory | -72 | 15 | -580.0% |
| Change in Accounts Payable | -13 | 78 | -116.7% |
| Change in Deferred Revenue | 506 | 456 | +11.0% |
| Net Cash from Operations | 1,014 | 1,270 | -20.2% |
| Investing Activities | |||
| Capital Expenditures | -314 | -285 | -10.2% |
| Net Cash from Investing | -304 | -304 | 0.0% |
| Financing Activities | |||
| Share Repurchases | -340 | -815 | +58.3% |
| Tax Withholding for Share Compensation | 28 | 27 | +3.7% |
| Net Cash from Financing | -515 | -777 | +33.7% |
| Supplemental | |||
| Income Taxes Paid | 304 | 284 | +7.0% |
| Interest Paid | 55 | 50 | +10.0% |
| Other Cash Flow | |||
| Net Change in Cash | 205 | 189 | +8.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.